ABBV
Price
$220.78
Change
+$4.52 (+2.09%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
382.04B
37 days until earnings call
JNJ
Price
$177.20
Change
+$0.74 (+0.42%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
424.98B
27 days until earnings call
Interact to see
Advertisement

ABBV vs JNJ

Header iconABBV vs JNJ Comparison
Open Charts ABBV vs JNJBanner chart's image
ABBVIE
Price$220.78
Change+$4.52 (+2.09%)
Volume$56.68K
Capitalization382.04B
Johnson & Johnson
Price$177.20
Change+$0.74 (+0.42%)
Volume$55.78K
Capitalization424.98B
ABBV vs JNJ Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. JNJ commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and JNJ is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (ABBV: $216.26 vs. JNJ: $176.46)
Brand notoriety: ABBV and JNJ are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 90% vs. JNJ: 95%
Market capitalization -- ABBV: $382.04B vs. JNJ: $424.98B
ABBV [@Pharmaceuticals: Major] is valued at $382.04B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $424.98B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $685.53B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • JNJ’s FA Score: 4 green, 1 red.
According to our system of comparison, both ABBV and JNJ are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 2 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • JNJ’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than JNJ.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +2.78% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -0.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.05%. For the same industry, the average monthly price growth was +0.38%, and the average quarterly price growth was +11.67%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

JNJ is expected to report earnings on Oct 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.05% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($425B) has a higher market cap than ABBV($382B). ABBV has higher P/E ratio than JNJ: ABBV (105.15) vs JNJ (18.89). ABBV (25.053) and JNJ (24.958) have similar YTD gains . JNJ has higher annual earnings (EBITDA): 35.6B vs. ABBV (14.2B). JNJ has more cash in the bank: 18.9B vs. ABBV (6.47B). JNJ has less debt than ABBV: JNJ (50.8B) vs ABBV (70.5B). JNJ has higher revenues than ABBV: JNJ (90.6B) vs ABBV (58.3B).
ABBVJNJABBV / JNJ
Capitalization382B425B90%
EBITDA14.2B35.6B40%
Gain YTD25.05324.958100%
P/E Ratio105.1518.89557%
Revenue58.3B90.6B64%
Total Cash6.47B18.9B34%
Total Debt70.5B50.8B139%
FUNDAMENTALS RATINGS
ABBV vs JNJ: Fundamental Ratings
ABBV
JNJ
OUTLOOK RATING
1..100
6861
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
931
SMR RATING
1..100
1332
PRICE GROWTH RATING
1..100
2932
P/E GROWTH RATING
1..100
1479
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JNJ's Valuation (15) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (88). This means that JNJ’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is in the same range as JNJ (31). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as JNJ (32). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.

ABBV's Price Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as JNJ (32). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.

ABBV's P/E Growth Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (79). This means that ABBV’s stock grew somewhat faster than JNJ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVJNJ
RSI
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
43%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
45%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
54%
MACD
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
43%
Advances
ODDS (%)
Bullish Trend 7 days ago
57%
Bullish Trend 16 days ago
42%
Declines
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
43%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
33%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
33%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AVSE63.820.46
+0.72%
Avantis Responsible Emerging Mkts Eq ETF
QQH74.73-0.04
-0.05%
HCM Defender 100 Index ETF
LFEQ52.65-0.06
-0.12%
VanEck Lg/Flat Trend ETF
AVRE45.04-0.15
-0.33%
Avantis Real Estate ETF
USMV93.10-0.39
-0.42%
iShares MSCI USA Min Vol Factor ETF